Areas of Expertise
Mergers and Acquisitions, Cross-border Investment, Private Equity Fund, Capital Markets, Energy, General Corporate and Securities Laws, Biotech and Pharmaceutical Laws
Track Record
- Representation of TXOne Network in its multi-series preferred shares fund raising and corporate restructuring
- Representation of Bora Pharmaceutical in the US$50M acquisition of Eden Biologics’ CDMO businesses and US$195M acquisition of 100% equity stake of TWi Pharmaceuticals
- Representation of MagiCapital in the US$138M acquisition of Ili Technology (a 100% subsidiary of MediaTek)
- Representation of Quaser Group (a Taiwan listed company) of its acquisition of Winbro Group (a US and UK company in aerospace industry) and obtain US CFIUS approval
- Representation of TPG Group’s acquisition of OPC Group (the top one CRO company in Taiwan)
- Representation of Guangdong Fenghua Advanced Technology (a Shenzhen listed company) in its tender offer of Viking Tech. (First tender offer deal of a Taiwan listed company by a PRC investor.)
- Representation of CID -led consortium in its tender offer and merger of Entire Technology and APEC (both are Taiwan listed companies).
- Representation of Bora Pharmaceutical’s acquisition of 100% shareholding in Impax Laboratories (a subsidiary of US Impax group) and various investment projects
- Representation of JEAN Group (a Taiwan listed company) in its asset sale to BOE Group (a Chinese SOE)
- Representation of Novartis in its transaction with GlaxoSmithKline (“GSK”) in the sale of Novartis’ non-influenza Vaccines business and acquisition of GSK’s oncology portfolio
- Representation of overseas Taiwanese investment in acquisition of targets in Europe, America and Asia
- Offshore PE fund formation in the form of limited partnership and segregated portfolio company (AI, real property, manufacturing, IOT industry and etc.) and subsequent fund investment
- Taiwan PE fund formation in the form of closed-end company and limited partnership (biotech, pharmaceutical, manufacturing, IT semiconductor, energy and etc.) and subsequent fund investment
- Representation of Venture Capital companies in their investment and disposal of portfolio companies
- Representation of pharmaceutical companies and biotech companies in their clinical trial, OEM, license agreement and co-development of pharmaceutical products with various business partners
- Representation of foreign investors and domestic private equity firms in the formation of energy funds and subsequent investments in solar energy projects
- Representation of IPO projects in Hong Kong Stock Exchange, Shanghai Stock Exchange and Taiwan Stock Exchange
Publications
- M&A Taiwan section (Lexology Getting the Deal Through Market Intelligence)
- Corporate M&A – Taiwan: Trends and Developments (Chambers Global Practice Guide)
- Acquisition Finance Taiwan section (Lexology Getting the Deal Through)
- Private Equity Taiwan section (Lexology in-depth)
- “Digit and Innovation: Intellectual Property Law Issues under the Open Banking Regime” (The Changing Fintech Laws by LCS Elites)
- “The Legal Challenge from Sharing Economy to Sharing Finance” (Fintech Development and Laws by LCS Elites)
- “The Prospect and Limitation of Fundraising Activities for Biotech Industries in Taiwan” (Legal Practice and Operation of Modern Businesses by LCS Elites)
- "Negotiation of Cross-Border Brand Licensing" (Business Law Commentary by LCS Elites)
- "Merger and Acquisition of REITs" (Trust Association)
- "Responsibilities of the trust enterprise, in its role as a trustee, acting as the proprietor of a building and recommendations" (Trust Association)
- "Fairness Test on Corporate Director's Self-Dealing: An Analysis of the Case of Weinberger v. UOP and Further Issues" (Cross-Strait Law Review)
.jpg)
